AVTX · Avalo Therapeutics, Inc.

The thesis

Avalo Therapeutics' abdakibart, an antibody for hidradenitis suppurativa (HS, a painful chronic skin disease), still has funded Phase 3 plans, but the market has cut its value sharply since AbbVie's rival lutikizumab reported Phase 3 data on 22 October 2026. The shares closed at $7.12 on 28 October 2026, against $12.01 on 15 October 2026.

AbbVie's release of 22 October 2026 said lutikizumab met its Week-16 primary endpoint, HiSCR75 (a 75% improvement in HS clinical response), at 31.4% against 23.4% on placebo, and met all eight ranked secondary endpoints. Fierce Biotech described the margin over placebo as narrower than expected. Between 22 October 2026 and 27 October 2026, Benzinga reported downgrades from H.C. Wainwright and Guggenheim to Neutral and target cuts from Wedbush (to $22), BTIG (to $10) and Oppenheimer.

The narrative is maturing: the Phase 2 topline has been public since 5 May 2026, and the analyst reset of 22 October to 27 October 2026 is now in the price. The 14-day relative strength index (RSI), a momentum gauge where readings under 30 mark heavy selling, was 18.5 on 28 October 2026. The three-month price change is -61.0%. Conviction stays low: the case for the asset is intact on the published data, but no company news has arrived to reverse the repricing.

Bullish and bearish views on Avalo Therapeutics, Inc.

The bull case on Avalo Therapeutics, Inc. (AVTX), in brief: Randomized efficacy supports Phase 3. The bear case: Analyst support has narrowed.

Bull case

• Randomized efficacy supports Phase 3. Avalo's 5 May 2026 release reported Week-16 HiSCR75 of 42.2% and 42.9% in the two abdakibart groups against 25.6% for placebo in the 253-patient Phase 2 LOTUS trial. Those rates are above the 31.4% AbbVie reported for lutikizumab in Phase 3, though the two trials are different studies.
• Cash covers the stated plan. Avalo reported $472.2 million in cash, cash equivalents and investments at 30 June 2026 and said on 6 August 2026 that it funds operations into 2029. On 16 September 2026 Chief Executive Garry Neil said at the H.C. Wainwright conference that capital should cover the Phase 3 topline readout.
• Some analysts kept constructive views. Benzinga reported on 23 October 2026 that Wedbush maintained Outperform with a $22 target and BTIG kept a positive rating with a $10 target. Leerink Partners initiated with Outperform and a $38 target on 6 July 2026; no change to that target appeared in company news through 28 October 2026.
• A positive Phase 3 validates the target class. AbbVie's trial was positive on its primary endpoint on 22 October 2026, and AbbVie guided to regulatory submissions in the second half of 2027.

Bear case

• Analyst support has narrowed. Benzinga reported on 23 October 2026 that H.C. Wainwright and Guggenheim cut their ratings to Neutral. BTIG's $10 target and Wedbush's $22 target followed, and Oppenheimer lowered its target on 27 October 2026.
• Competitor results reset expectations. Benzinga's 22 October 2026 coverage linked Avalo's drop to AbbVie's INTREPID data, and one analyst cited by press reports pointed to the modest lutikizumab effect. The market is now judging the HS class on a smaller drug-versus-placebo gap than Phase 2 suggested.
• Differentiation is unproven. LOTUS compared abdakibart with placebo only, so its standing against approved HS antibodies rests on cross-trial comparisons.
• Insiders have pre-scheduled sales. At least two officer Rule 10b5-1 plans (adopted 13 November 2025 and 18 May 2026) are live, so planned sales can print without new company information.
• No pivotal readout is near. The Phase 3 start is guided to the first half of 2027, so interim news is regulatory, financial or tied to medical congresses.

Price setup

The adjusted close was $7.12 on 28 October 2026, 68.9% below the 52-week high of $22.87. The $10.50 level named in the previous note was broken on the way down.

The RSI of 18.5 shows heavy selling; whether it is exhausted is not shown by the price history. Weighted average shares were 43,602,044 in Q2 2026 against average daily volume near 1.16 million, so news clears at wide price increments.

Crowding evidence points to a position that has already been marked down: five analyst actions in six sessions, an earnings report about a week away, and live officer sale plans. No Form 4 filings or other SEC filings appeared in the past 30 days.

Catalysts, next 30 days

• H2 2026, guided: End-of-Phase-2 FDA meeting. An agreed Phase 3 design supports the first-half 2027 start; a request for more work weakens the funded-development case. Timing inside the half is not disclosed.
• 30 June 2027: End of the guided Phase 3 initiation window. A start inside it keeps management's timetable. This date falls outside the next 30 days and is listed because the case turns on it.

Elapsed catalysts

• ~5 November 2026, est.: Q3 2026 financial results and business update. First company comment since the AbbVie data, on spending against $472.2 million in cash and on the Phase 3 timetable. The date is unconfirmed; last year's report came on 6 November 2025. (passed 1d ago)

What would change the view

The case breaks if the FDA asks for another Phase 2 trial, if Phase 3 initiation slips past 30 June 2027, or if Avalo says existing cash cannot fund the Phase 3 topline readout. A daily close below $6.00 would also end it, extending the decline beyond the $7.12 close of 28 October 2026.

Evidence that would strengthen it: a company statement after the FDA meeting confirming the Phase 3 design and start timing, or a Q3 report showing spending in line with the 2029 runway. Reinstated ratings from H.C. Wainwright or Guggenheim would show analysts reversing the October view.

What it trades with

AVTX trades on its own clinical and regulatory news. In October its largest move tracked a competitor's Phase 3 result, AbbVie's lutikizumab on 22 October 2026, rather than the broad market, which Benzinga recorded as the Nasdaq falling 400 points that same session. Avalo joined the Russell 2000 and Russell 3000 indexes on 26 June 2026, so small-cap fund flows can affect it. Other HS developers and any further INTREPID detail from AbbVie are the nearest read-throughs.